Medication review with follow-up for cardiovascular outcomes: a trial based cost–utility analysis

Antonio Ahumada-Canale; Constanza Vargas; Carlos Balmaceda; Francisco Martinez-Mardones; José Cristian Plaza-Plaza; Shalom Benrimoj; Victoria Garcia-Cardenas

doi:10.2217/cer-2020-0171

Medication review with follow-up for cardiovascular outcomes: a trial based cost–utility analysis

Antonio Ahumada-Canale, Constanza Vargas, Carlos Balmaceda, Francisco Martinez-Mardones, José Cristian Plaza-Plaza, Shalom Benrimoj, Victoria Garcia-Cardenas

Macquarie University Centre for the Health Economy

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

Aim: To assess the trial-based cost–effectiveness of medication review with follow-up comparedwith usual care in primary care.

Materials & methods: A cluster randomized controlled trial included patients if they were independent older adults, receiving five or more prescriptions, with moderate or high cardiovascular risk. Costs were estimated from the public healthcare sector perspective, and health benefits were measured as quality-adjusted life years. Both of which were used to calculate the incremental cost– effectiveness ratio.

Results: Twelve centers completed the study, six (146 patients) in the intervention group and six (145 patients) in the control group. The base-case analysis showed an incremental cost–effectiveness ratio of US$ (2019) 434.4/quality-adjusted life year (95% CI 64.20–996.03).
Conclusion: The intervention was cost-effective in the public primary care setting.

Original language	English
Pages (from-to)	229-242
Number of pages	14
Journal	Journal of Comparative Effectiveness Research
Volume	10
Issue number	3
DOIs	https://doi.org/10.2217/cer-2020-0171
Publication status	Published - Feb 2021

Keywords

aged
cardiovascular system
cost–effectiveness
drug monitoring
economics
pharmacy

Access to Document

10.2217/cer-2020-0171

Cite this

@article{c7cd9f5ad29048bfb21106266de7bbc3,

title = "Medication review with follow-up for cardiovascular outcomes: a trial based cost–utility analysis",

abstract = "Aim: To assess the trial-based cost–effectiveness of medication review with follow-up comparedwith usual care in primary care.Materials & methods: A cluster randomized controlled trial included patients if they were independent older adults, receiving five or more prescriptions, with moderate or high cardiovascular risk. Costs were estimated from the public healthcare sector perspective, and health benefits were measured as quality-adjusted life years. Both of which were used to calculate the incremental cost– effectiveness ratio.Results: Twelve centers completed the study, six (146 patients) in the intervention group and six (145 patients) in the control group. The base-case analysis showed an incremental cost–effectiveness ratio of US$ (2019) 434.4/quality-adjusted life year (95% CI 64.20–996.03).Conclusion: The intervention was cost-effective in the public primary care setting.",

keywords = "aged, cardiovascular system, cost–effectiveness, drug monitoring, economics, pharmacy",

author = "Antonio Ahumada-Canale and Constanza Vargas and Carlos Balmaceda and Francisco Martinez-Mardones and Plaza-Plaza, {Jos{\'e} Cristian} and Shalom Benrimoj and Victoria Garcia-Cardenas",

year = "2021",

month = feb,

doi = "10.2217/cer-2020-0171",

language = "English",

volume = "10",

pages = "229--242",

journal = "Journal of Comparative Effectiveness Research",

issn = "2042-6305",

publisher = "Future Medicine",

number = "3",

}

TY - JOUR

T1 - Medication review with follow-up for cardiovascular outcomes

T2 - a trial based cost–utility analysis

AU - Ahumada-Canale, Antonio

AU - Vargas, Constanza

AU - Balmaceda, Carlos

AU - Martinez-Mardones, Francisco

AU - Plaza-Plaza, José Cristian

AU - Benrimoj, Shalom

AU - Garcia-Cardenas, Victoria

PY - 2021/2

Y1 - 2021/2

N2 - Aim: To assess the trial-based cost–effectiveness of medication review with follow-up comparedwith usual care in primary care.Materials & methods: A cluster randomized controlled trial included patients if they were independent older adults, receiving five or more prescriptions, with moderate or high cardiovascular risk. Costs were estimated from the public healthcare sector perspective, and health benefits were measured as quality-adjusted life years. Both of which were used to calculate the incremental cost– effectiveness ratio.Results: Twelve centers completed the study, six (146 patients) in the intervention group and six (145 patients) in the control group. The base-case analysis showed an incremental cost–effectiveness ratio of US$ (2019) 434.4/quality-adjusted life year (95% CI 64.20–996.03).Conclusion: The intervention was cost-effective in the public primary care setting.

AB - Aim: To assess the trial-based cost–effectiveness of medication review with follow-up comparedwith usual care in primary care.Materials & methods: A cluster randomized controlled trial included patients if they were independent older adults, receiving five or more prescriptions, with moderate or high cardiovascular risk. Costs were estimated from the public healthcare sector perspective, and health benefits were measured as quality-adjusted life years. Both of which were used to calculate the incremental cost– effectiveness ratio.Results: Twelve centers completed the study, six (146 patients) in the intervention group and six (145 patients) in the control group. The base-case analysis showed an incremental cost–effectiveness ratio of US$ (2019) 434.4/quality-adjusted life year (95% CI 64.20–996.03).Conclusion: The intervention was cost-effective in the public primary care setting.

KW - aged

KW - cardiovascular system

KW - cost–effectiveness

KW - drug monitoring

KW - economics

KW - pharmacy

UR - http://www.scopus.com/inward/record.url?scp=85101083686&partnerID=8YFLogxK

U2 - 10.2217/cer-2020-0171

DO - 10.2217/cer-2020-0171

M3 - Article

C2 - 33543637

SN - 2042-6305

VL - 10

SP - 229

EP - 242

JO - Journal of Comparative Effectiveness Research

JF - Journal of Comparative Effectiveness Research

IS - 3

ER -

Medication review with follow-up for cardiovascular outcomes: a trial based cost–utility analysis

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

A health-check for sick spending in Chile

Cost-utility analysis of pharmacist-led medication review in primary care patients with hypertension, type 2 diabetes mellitus and dyslipidaemia

Economic Evaluation of Pharmacist-led Medication Review in the Primary Health Care Centres in Chile

Cite this

Medication review with follow-up for cardiovascular outcomes: a trial based cost–utility analysis

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Press/Media

A health-check for sick spending in Chile

Activities

Cost-utility analysis of pharmacist-led medication review in primary care patients with hypertension, type 2 diabetes mellitus and dyslipidaemia

Research output

Economic Evaluation of Pharmacist-led Medication Review in the Primary Health Care Centres in Chile

Cite this